Seagen teams up with protein degradation specialist to make a new kind of antibody conjugate, paying $60M upfront

Seagen, whose suite of antibody-drug conjugates enticed Pfizer to a $43 billion buyout, is looking to put a twist on the idea.

The Seattle-based drugmaker will team up with Nurix to develop degrader-antibody conjugates (DAC), in a bid to combine their expertise in ADCs and protein degradation. Seagen is handing over $60 million upfront to start the deal, which can also deliver $3.4 billion in milestones to Nurix, on top of future royalties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

A new study of sick infants sees potential in DNA sequencing, but also a need for better ways to interpret the genome

There’s growing evidence that DNA sequencing can help diagnose the health care system’s youngest patients — babies in their first year of life. But a

July 11, 2023

Genentech’s food allergy medication gets priority review nod from the FDA

Genentech’s Xolair scored a priority review from the FDA on Wednesday for the reduction of allergic reactions in adult and pediatric patients 1 year and

December 21, 2023

Poverty and mental Illness: A causal relationship revealed

Poverty and mental illness are not only linked, but there is also a causal relationship. This is the conclusion of researchers from Amsterdam UMC, the

July 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.